A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer ; volume:6 ; number:1 ; day:27 ; month:2 ; year:2018 ; pages:1-14 ; date:12.2018
Journal for ImmunoTherapy of Cancer ; 6, Heft 1 (27.2.2018), 1-14, 12.2018
- Urheber
-
Engel-Riedel, Walburga
- Beteiligte Personen und Organisationen
-
Lowe, Jamie
Mattson, Paulette
Richard Trout, J.
Huhn, Richard D.
Gargano, Michele
Patchen, Myra L.
Walsh, Richard
Trinh, My My
Dupuis, Mariève
Schneller, Folker
SpringerLink (Online service)
- DOI
-
10.1186/s40425-018-0324-z
- URN
-
urn:nbn:de:1111-20180424610
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Engel-Riedel, Walburga
- Lowe, Jamie
- Mattson, Paulette
- Richard Trout, J.
- Huhn, Richard D.
- Gargano, Michele
- Patchen, Myra L.
- Walsh, Richard
- Trinh, My My
- Dupuis, Mariève
- Schneller, Folker
- SpringerLink (Online service)
Ähnliche Objekte (12)
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: results of the NEPTUN study
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: final results of the NEPTUN study
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study
Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
Paclitaxel und Paclitaxel-Carboplatin beim fortgeschrittenen nichtkleinzelligen Bronchialkarzinom : Auswertung klinischer Phase-II-Studien
To assess the role of addition of bevacizumab therapy to carboplatin and paclitaxel as frontline treatment of epithelial ovarian cancer
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
Nab-Paclitaxel + Carboplatin bei fortgeschrittenem NSCLC : Fallsamlung von 7 Kasuistiken
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: results of the NEPTUN study
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: final results of the NEPTUN study
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study
Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
Paclitaxel und Paclitaxel-Carboplatin beim fortgeschrittenen nichtkleinzelligen Bronchialkarzinom : Auswertung klinischer Phase-II-Studien
To assess the role of addition of bevacizumab therapy to carboplatin and paclitaxel as frontline treatment of epithelial ovarian cancer
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
Nab-Paclitaxel + Carboplatin bei fortgeschrittenem NSCLC : Fallsamlung von 7 Kasuistiken
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: results of the NEPTUN study
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: final results of the NEPTUN study
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study
Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
Paclitaxel und Paclitaxel-Carboplatin beim fortgeschrittenen nichtkleinzelligen Bronchialkarzinom : Auswertung klinischer Phase-II-Studien
To assess the role of addition of bevacizumab therapy to carboplatin and paclitaxel as frontline treatment of epithelial ovarian cancer
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France